Efficacy and Safety of Mirodenafil in Men Taking Antihypertensive Medications

Jae Seung Paick, Je-Jong Kim, Sae Chul Kim, Ki Hak Moon, Kweon Sik Min, Kwangsung Park, Jun Kyu Suh, Dae Yul Yang

    Research output: Contribution to journalArticlepeer-review

    16 Citations (Scopus)


    Introduction: Mirodenafil is a recently developed oral phosphodiesterase type 5 inhibitor, which was observed to significantly improve erectile function and was well tolerated in men with broad-spectrum erectile dysfunction (ED). Aim: To investigate the efficacy and safety of mirodenafil treatment compared with placebo in men taking at least one antihypertensive medication. Methods: A multicenter, double-blind, placebo-controlled, parallel group, fixed-dose study was conducted with 109 subjects who were randomized to placebo or mirodenafil 100 mg for 12 weeks on an " as needed" basis. Main Outcome Measures: The primary efficacy measures were the changes from baseline in sum of scores on International Index of Erectile Function-erectile function domain (IIEF-EF) questions 1 to 5 and 15 with treatment. The secondary efficacy measures included scores on IIEF question 3 and 4 (Q3 and Q4), all domain scores of IIEF, and Sexual Encounter Profile Question 2 and 3 (SEP2 and SEP3) along with responses to Global Assessment Question (GAQ) and Life Satisfaction Checklist (LSC). The safety assessments included laboratory tests, vital signs, 12-lead electrocardiogram recordings, and patients' reporting of adverse events. Results: The mirodenafil group showed significantly greater increase in IIEF-EF scores at 12 weeks compared with the placebo group (9.35 ± 6.86 vs. 2.66 ± 6.44, P < 0.001). The mirodenafil group also demonstrated significantly greater improvement in scores of IIEF Q3 and Q4, other four domains of IIEF, SEP2, SEP3, and LSC along with percentages of patients responding positively to GAQ compared with the placebo group. During the study, no clinically significant changes were observed regarding blood pressure, heart rate, electrocardiographic findings, or laboratory values. Facial flushing and headache were the most common treatment-associated adverse events, which were mild or moderate in severity, resolving spontaneously. Conclusions: Mirodenafil was effective and safe in men with ED concomitantly taking antihypertensive medications.

    Original languageEnglish
    Pages (from-to)3143-3152
    Number of pages10
    JournalJournal of Sexual Medicine
    Issue number9
    Publication statusPublished - 2010 Jan 1


    • Antihypertensives
    • Erectile dysfunction
    • Mirodenafil
    • PDE5 inhibitor

    ASJC Scopus subject areas

    • Reproductive Medicine
    • Obstetrics and Gynaecology
    • Urology


    Dive into the research topics of 'Efficacy and Safety of Mirodenafil in Men Taking Antihypertensive Medications'. Together they form a unique fingerprint.

    Cite this